TuHURA Biosciences, Inc.

What they do

TuHURA develops technologies intended to overcome primary and acquired resistance to cancer immunotherapies. Its lead candidate, IFx-2.0, is an innate immune agonist in a Phase 3 registration trial as an adjunct to Keytruda (pembrolizumab) in first-line advanced or metastatic Merkel cell carcinoma. Through its June 2025 acquisition of Kineta, it also holds TBS-2025 (formerly KVA1213), a VISTA-inhibiting monoclonal antibody it plans to study in mutated NPM1 AML. The company has no approved products and has generated no revenue from product sales.

Revenue drivers

• IFx-2.0 (Immune Fx platform) — Lead innate immune agonist candidate in a Phase 3 trial in Merkel cell carcinoma with Keytruda; no revenue, as the company has no approved products and reports $0 revenue.
• TBS-2025 (VISTA-inhibiting antibody) — Acquired with Kineta in June 2025; IND filed for molecularly defined AML subsets, with a planned Phase 1b/2 trial in mut NPM1 relapsed/refractory AML; pre-revenue.
• MDSC Inhibitors (bi-specific ADCs) — Earlier-stage program whose in vivo proof-of-concept studies were targeted to begin in the second half of 2026; pre-revenue.
• Financing, not product sales — Operations are funded by capital raises and debt rather than revenue: a $50 million credit facility from the largest shareholder, ATM sales, and the Parkview credit facility.

Recent performance

Second quarter 2026 R&D expense was $6.6 million versus $4.9 million a year earlier, and G&A was $2.1 million versus $1.9 million. Net cash used in operating activities was $13.0 million for the six months ended June 30, 2026, compared with $10.9 million in the prior-year period. Cash and cash equivalents were $1.0 million at June 30, 2026, with total assets of $31.7 million, total liabilities of $13.2 million and shareholder equity of $18.5 million. The company reported $0 revenue for the quarter and year-to-date. Full-year 2025 net loss was reported at $30.1 million in the 10-K MD&A, with an accumulated deficit of $141.2 million as of December 31, 2025.

Strategy

Management is prioritizing clinical execution across three programs: IFx-2.0 in Merkel cell carcinoma, TBS-2025 in mut NPM1 AML, and MDSC inhibitor bi-specific ADCs. In April 2026 the company announced a $50 million credit facility with royalty transaction from its largest shareholder, described as a non-convertible source of operating capital with an anticipated cash runway into 2028, drawable as needed to fund monthly expenses and bearing 12% annual interest with principal due at April 21, 2031 maturity. The company also raised $0.3 million in April 2026 and $0.1 million in July 2026 under its ATM program and has drawn $5.7 million in gross proceeds to date on the Parkview credit facility, including $2.15 million after June 30, 2026. Stated near-term priorities include orphan drug designations in MCC for IFx-2.0 and in AML for TBS-2025.

Risks

• No revenue and continuing losses — The company has never generated product revenue, reported $0 revenue, and had an accumulated deficit of $141.2 million as of December 31, 2025, with losses expected to increase.
• Very low cash balance — Cash and cash equivalents were only $1.0 million at June 30, 2026, leaving operations dependent on drawdowns from the $50 million shareholder credit facility and further ATM or other financings.
• Clinical and regulatory uncertainty — The lead Phase 3 IFx-2.0 trial in Merkel cell carcinoma relies on the FDA accelerated approval pathway, and TBS-2025 is still pre-Phase 1b/2, so timelines and outcomes are unproven.
• Dependence on a related-party lender — The $50 million credit facility was provided by the company's largest shareholder at 12% annual interest, concentrating financing reliance on a single related party.

Outlook

Management targets several second-half 2026 milestones: safe-to-proceed FDA feedback and initiation of the Phase 1b/2 TBS-2025 trial in mut NPM1 relapsed/refractory AML; potential orphan drug designation in MCC for IFx-2.0 and in AML for TBS-2025; and initiation of in vivo proof-of-concept studies for MDSC inhibitor bi-specific ADCs. Preliminary IFx-2.0 results from an IR study with Keytruda in deep-seated MCC are expected in the first half of 2027, with Phase 3 enrollment completion targeted for the second half of 2027. The company states the $50 million credit facility provides runway it expects to extend into 2028.